Applied Filters
What drives the urge to merge?
There is some debate about whether the ‘patent cliff’ or the need to innovate is driving M&A activity in the pharmaceutical industry, where billions of dollars have been spent in the past few years, as LSIPR finds out.
Event preview: Life Sciences Patents Network Europe 2016
On December 7, LSIPR will be hosting the Life Sciences Patents Network Europe 2016 at the Bloomsbury Hotel in London. Here we preview the main talking points.
LSIPR 50 2016: Giles Platford and Pardis Sabeti
Giles Platford and Pardis Sabeti were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Platford and Sabeti were featured in the business and innovation section, as LSIPR reports.
LSIPR 50 2016: Patricia LiWang and Sir Paul Nurse
Patricia LiWang and Sir Paul Nurse were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. LiWang and Nurse were featured in the business and innovation section, as LSIPR reports.
LSIPR 50 2016: Galit Gonen
Galit Gonen was selected in the LSIPR 50 2016 publication for her influence on the life sciences industry. Gonen was featured in the legal section, as LSIPR reports.
LSIPR 50 2016: Guido Rasi and Luis Salaices
Guido Rasi and Luis Salaices were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Rasi and Luis Salaices were featured in the government and policy section, as LSIPR reports.
LSIPR 50 2016: James Love
James Love was selected in the LSIPR 50 2016 publication for his influence on the life sciences industry. Love featured in the government and policy section, as LSIPR reports.
LSIPR 50 2016: Xi Jinping and George Freeman
Xi Jinping and George Freeman were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Jinping and Freeman were featured in the government and policy section, as LSIPR reports.
Mind your language
A decision by Germany’s Federal Court of Justice has developed the concept of the ‘doctrine of equivalents’, possibly benefiting pharma patent owners, say Bernd Allekotte and Markus Grammel of Grünecker.
Preview: Life Sciences IP Summit 2016
Ahead of the Life Sciences IP Summit 2016 from October 20 to 21 at the Hilton London Paddington Hotel, Sarah Porch of C5 previews the main talking points, including Brexit and the UPC.
